According to the Legislative Budget Board (LBB), HB 107 is projected to have a negative net fiscal impact of approximately $4.8 million on General Revenue over the 2026–2027 biennium. The bill does not make a direct appropriation but establishes the statutory framework for potential future appropriations needed to implement the Sickle Cell Disease Registry program through the Department of State Health Services (DSHS).

The bulk of the fiscal impact stems from startup and operational costs associated with establishing and maintaining the registry. In fiscal year 2026, estimated costs are over $3.3 million, followed by approximately $1.4 million in fiscal year 2027. These costs include hiring five full-time equivalent (FTE) staff members, such as epidemiologists, program specialists, and IT analysts, who will oversee data collection, management, system development, and report publication.

The technology investment required to build the registry accounts for a significant portion of the costs. DSHS plans to create a standalone system modeled on an existing health registry. IT-related expenses in 2026 include $1.15 million for staff augmentation, $350,000 for new hardware, $300,000 for software licenses, and additional expenditures for system integration, identity management, and reporting platforms. Total technology-related costs for 2026 alone exceed $2.8 million, with a smaller recurring investment in 2027.

The Legislative Budget Board found no significant fiscal impact on local governments, indicating the financial responsibility for implementation lies primarily with the state.

HB 107 proposes the creation of a statewide Sickle Cell Disease Registry under the Texas Department of State Health Services (DSHS), with the goal of improving care coordination, diagnosis, and research for individuals living with sickle cell disease. While the public health intent behind the bill is commendable, especially given the disproportionate impact of the disease on underserved communities, the mechanism it employs raises significant concerns from a fiscal and limited-government perspective.

The bill would result in an estimated $4.8 million cost to General Revenue over the 2026–2027 biennium, primarily to support new staff, infrastructure, and IT system development. These are not one-time expenses but introduce a new line of recurring costs to the state budget with no built-in mechanisms for accountability, performance tracking, or fiscal review. Moreover, the creation of this new registry expands the responsibilities of DSHS by adding an additional disease-specific program, setting a precedent for further bureaucratic growth without a clear threshold for impact or consolidation with existing systems.

Importantly, HB 107 does not include a sunset clause, cost-benefit review, or clear metrics to determine the registry's long-term value. It lacks assurances that this new initiative will produce measurable health improvements or cost savings, raising the concern that the state is expanding its administrative reach without sufficient justification. In a state that prioritizes fiscal discipline and limited government, this kind of expansion—even for a good cause—must meet a high threshold for necessity and efficiency.

For these reasons, while the goals of HB 107 are admirable, the absence of fiscal guardrails and the potential for long-term bureaucratic growth are reasons why Texas Policy Research recommends that lawmakers vote NO on HB 107.

• Individual Liberty: The bill enhances individual liberty by aiming to improve access to accurate diagnoses, coordinated care, and potentially life-saving treatment for people with sickle cell disease. Since the registry is designed to protect patient confidentiality through compliance with HIPAA and state privacy laws, it upholds the right to personal health privacy while enabling better outcomes for affected individuals.
• Personal Responsibility: The bill does not impose any obligations on individuals or encourage self-directed behavior changes. It is a systems-level intervention designed to help healthcare providers and public health officials. While patients may benefit from improved care coordination, the bill does not explicitly promote or discourage personal responsibility in health decision-making.
• Free Enterprise: The bill requires health care facilities to report cases of sickle cell disease, adding a modest administrative burden to hospitals and diagnostic centers. However, these types of reporting mandates already exist for other diseases in Texas (e.g., cancer, trauma). The impact on private business operations is minimal, but it does represent an additional state-imposed compliance task.
• Private Property Rights: The bill does not interfere with land, physical property, or contractual agreements. Although it involves the collection of health data, that data is handled within the boundaries of current privacy laws, and no new data-sharing powers or seizures are authorized.
• Limited Government: This is where the bill raises the most concern. The bill creates a new government program, adds five new full-time employees, and expands the administrative scope of the Department of State Health Services. The lack of a sunset provision, cost controls, or performance auditing further compounds concerns about unchecked bureaucratic growth. While the bill has a focused mission, it still represents an expansion of government infrastructure with recurring costs and precedent-setting implications.

• HB 1884 (Same As)
• SB 820 (Same As)